{"entity":{"id":"cdk2","kind":"target","name":"CDK2","aka":["cyclin dependent kinase 2","Cyclin-dependent kinase 2"],"tldr":"CDK2 (Cyclin-dependent kinase 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Triple-negative breast cancer.","summary":"Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CABLES1, CTNNB1, CDK2AP2, ERCC6, NBN, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, SUV39H1, EZH2. Triggers duplication of centrosomes and DNA.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Carboplatin and Eribulin. In OnCo, 1 product record names it (AVZO-021).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:1771","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1771"},{"label":"UniProt P24941","url":"https://www.uniprot.org/uniprotkb/P24941/entry"},{"label":"NCBI Gene 1017","url":"https://www.ncbi.nlm.nih.gov/gene/1017"},{"label":"Ensembl ENSG00000123374","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123374"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["avzo-021"],"companies":[],"institutions":[],"pathways":["dna-replication-licensing","sclc-signalling"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; CIViC holds 1 clinical evidence items on its variants; UniProt keyword \"DNA repair\". Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"CDK2","role":["drug-target","biomarker","dna-repair"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:1771","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1771","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P24941","url":"https://www.uniprot.org/uniprotkb/P24941/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene CDK2","url":"https://civicdb.org/features/906","note":"1 evidence items, 0 assertions, 1 variants; diseases: Triple-negative Breast Cancer (GraphQL API, CC0)"}],"hgnc":"HGNC:1771","ensembl":"ENSG00000123374","uniprot":"P24941","entrez":"1017","biology":"Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CABLES1, CTNNB1, CDK2AP2, ERCC6, NBN, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, SUV39H1, EZH2. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus. Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in embryonic stem cells (ESCs). Activated by the CDK-activating kinase (CAK) complex consisting of CDK7, cyclin-H/CCNH and MAT1, which is a master regulator of CDK activity. Location: Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Nucleus, Cajal body; Cytoplasm; Endosome (UniProt). Locus 12q13.2 (HGNC).","whereFound":["Triple-negative breast cancer: CIViC evidence names this disease"],"targetClass":"kinase","prevalence":[]},"route":"/targets/cdk2/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"avzo-021","kind":"drug","name":"AVZO-021","route":"/drugs/avzo-021/"}],"pathway":[{"id":"dna-replication-licensing","kind":"pathway","name":"DNA replication & origin licensing","route":"/pathways/dna-replication-licensing/"},{"id":"sclc-signalling","kind":"pathway","name":"Small cell lung cancer (KEGG map)","route":"/pathways/sclc-signalling/"}]}}